Latest Sales Guidance News

Universal Store Holdings has posted a 14% rise in retail sales for the first 43 weeks of FY26, buoyed by strong like-for-like growth across its brands. However, ongoing wholesale challenges at CTC have triggered a $24 million impairment, even as the group maintains its full-year sales and EBITA guidance.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

Paladin Energy has lifted its uranium production guidance for FY2026 at the Langer Heinrich Mine, citing strong ramp-up progress and improved processing metrics. The company also trimmed capital expenditure forecasts while maintaining sales and cost outlooks amid geopolitical uncertainties.

Vmoto Limited forecasts FY26 sales revenue between $73.5 million and $85 million, marking a 57% to 82% increase over FY25, driven by growing orders, strategic partnerships, and regulatory trends favouring electric motorcycles in key markets.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

Elevra Lithium reported solid Q2 FY26 production and revenue results while progressing its North American Lithium brownfield expansion and forging strategic supply partnerships.

MGX Resources reported a $20.8 million half-year loss, driven by a major rockfall at Koolan Island that halted mining and triggered a $60 million asset impairment. The company is pivoting towards gold with its recent acquisition of a 50% stake in the Central Tanami Project.

Elevra Lithium Limited reported record quarterly revenue and gross profit at its North American Lithium operation, even as it navigates short-term production challenges and revises FY2026 guidance downward.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Fenix Resources has achieved a record quarterly iron ore shipment of 1.2 million tonnes, driving a strong cash increase to A$79 million and reaffirming its FY26 production guidance.

Vita Life Sciences forecasts solid sales and profit growth for FY2025, driven by strong performances in Malaysia and Singapore, while cautiously managing challenges in China exports.